Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of Bromantane and Semax — mechanism, dosing, side effects, legal status, and pricing.
Bromantane (Ladasten) is a synthetic adamantane-derivative small molecule — not a peptide — developed in Russia as an "actoprotector"/adaptogen with combined mild psychostimulant and anxiolytic activity. It is an approved prescription drug in Russia (Ladasten) for asthenic disorders, but it has no FDA or EMA approval and no blinded, placebo-controlled human trials. It is prohibited in sport (WADA S6 stimulant) and circulates on the gray market as a research chemical.
Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) derived from ACTH(4-10) with a Pro-Gly-Pro C-terminal extension for metabolic stability. It was developed at the Institute of Molecular Genetics (Russian Academy of Sciences) and registered as a drug in Russia in 1994. It is not FDA-approved.
Bromantane
Semax
Category
Legal Status
Mechanism
Dose Range
Route
Frequency
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
Bromantane
No pricing data yet.
Check Bromantane prices →Semax
COA corpus from Disclosed Labs — independently tested batches only.
Bromantane
4
COAs
99.9%
Avg purity
3
Labs
Semax
82
COAs
99.5%
Avg purity
16
Labs
Human evidence is limited to Russian clinical use of Ladasten. The largest published dataset is an open-label, non-comparative multicenter trial (28 centers, N=728) in asthenic disorder at 50–100 mg/day for 28 days (Voznesenskaia et al., 2010), reporting symptomatic improvement (CGI-S response 76.0%, CGI-I 90.8%) with adverse effects in ~3% of patients. No blinded, placebo-controlled randomized trial exists and there is no ClinicalTrials.gov registration. All mechanistic and toxicology data are preclinical (rat, mouse, in-vitro). Approved only in Russia; not FDA/EMA-approved; not a peptide.
Key references
Semax's evidence base is primarily Russian-language clinical literature. Gusev, Skvortsova and colleagues reported improved neurological recovery in acute hemispheric ischemic stroke when Semax was added to conventional therapy (Zh Nevrol Psikhiatr, 1997; PMID 11517472), and subsequent Russian studies extended use to cerebrovascular insufficiency (PMID 15792140). Preclinical work by Dolotov, Myasoedov and colleagues demonstrated that intranasal Semax rapidly elevates BDNF protein and TrkB activation in rat hippocampus and basal forebrain (Brain Res 2006, PMID 16996037; J Neurochem 2006, PMID 16635254). Genome-wide transcriptional analysis by Medvedeva et al. in rat focal ischemia showed Semax modulates a broad panel of immune-response and vascular-system genes (BMC Genomics 2014, PMID 24661604). Western evidence is limited; Semax has not been evaluated by the FDA and has no pivotal trials in the US or EU.
Key references
Bromantane and Semax are both in the Cognitive category and may have overlapping mechanisms. Researchers should review both profiles carefully, understand the mechanisms of action, and monitor the relevant biomarkers when combining compounds in the same class. As always, consult a licensed healthcare provider before making any decisions about combining research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Dosing Notes
Half-life
Side Effects
Contraindications
Lab Testing
Disclosed Labs